PAS
SUPN icon

Point72 Asia (Singapore)’s Supernus Pharmaceuticals SUPN Stock Holding History

Point72 Asia (Singapore)’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,587
Closed -$84.7K – 1253
2025
Q1 		$84.7K Buy
2,587
+2,378
+1,138% +$84.3K 0.02% 449
2024
Q4 		$7.55K Buy
209
+65
+45% +$2.29K ﹤0.01% 767
2024
Q3 		$4.48K Sell
144
-697
-83% -$21.8K ﹤0.01% 885
2024
Q2 		$22.5K Sell
841
-4,073
-83% -$118K ﹤0.01% 816
2024
Q1 		$168K Buy
+4,914
New +$146K 0.04% 495

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Point72 Asia (Singapore)'s SUPN Position: Q2 2025 in Review

Point72 Asia (Singapore) sold out of Supernus Pharmaceuticals (SUPN) in Q2 2025, closing a stake of 2,587 shares — an estimated $84.7K sold.

Point72 Asia (Singapore) first reported a position in SUPN in Q1 2024 and held it in 5 quarters. The position peaked at $168K in Q1 2024. 295 funds tracked by Wall St. Rank hold SUPN as of Q2 2025.

  • Point72 Asia (Singapore) reported no remaining Supernus Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 2,587 Supernus Pharmaceuticals shares in Q2 2025, an estimated $84.7K.
  • Point72 Asia (Singapore) first reported a position in Supernus Pharmaceuticals in Q1 2024 and held it in 5 quarters.
  • Point72 Asia (Singapore)'s Supernus Pharmaceuticals position peaked at $168K in Q1 2024.
  • 295 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q2 2025, filed 14 Aug 2025.